Literature DB >> 23778314

Naturally occurring IgG antibody levels to the Staphylococcus aureus protein IsdB in humans.

Julie K Zorman1, Mark Esser, Michael Raedler, Barry N Kreiswirth, Dlawer A A Ala'Aldeen, Nicholas Kartsonis, Steven S Smugar, Annaliesa S Anderson, Tessie McNeely, Jean Marie Arduino.   

Abstract

Staphylococcus aureus is a well-recognized, clinically important cause of nosocomial infections, and as such, a vaccine to prevent S. aureus infections would be an important achievement. A Phase IIB/III study of V710, a vaccine containing iron-regulated surface determinant B (IsdB), demonstrated significant sero-conversion rates in cardiovascular surgery patients following a single pre-surgery immunization. However, the vaccine was not efficacious in preventing bacteremia or deep sternal wound infection post-surgery, thus raising the possibility that IsdB might not be available for immune recognition during infection. The purpose of the work described herein was to evaluate and quantify the naturally occurring anti-IsdB levels at baseline and over time during infection, to understand whether IsdB is expressed during a S. aureus infection in hospitalized non-vaccinated patients. We evaluated baseline and follow-up titers in 3 populations: (1) healthy subjects, (2) hospitalized patients with non-S. aureus infections, and (3) hospitalized patients with S. aureus infections. Baseline anti-IsdB levels generally overlapped between the 3 groups, but were highly variable within each group. In healthy subjects, baseline and follow-up levels were highly correlated (Spearman's rho = 0.93), and the geometric mean fold-rise (GMFR) in anti-IsdB levels between study entry and last value was 0.9-fold (95% confidence interval (CI): 0.8 to 1.0 ; p = 0.09), showing no trend over time. The convalescent GMFR in anti-IsdB levels from baseline was 1.7-fold (95% CI: 1.3 to 2.2, p = 0.0008) during S. aureus infection, significantly different from the 1.0-fold GMFR (95% CI: 0.9-1.2, p = 0.60) in non-S. aureus infection, p = 0.005. Additionally, S. aureus isolates (51) obtained from the hospitalized patient group expressed the IsdB protein in vitro. Collectively, these data suggest that IsdB expression levels rise substantially following infection with S. aureus, but not with other pathogens, and IsdB is likely well-conserved across S. aureus strains.

Entities:  

Keywords:  IsdB; S. aureusinfection; antibody levels; healthy subjects; hospitalized patients

Mesh:

Substances:

Year:  2013        PMID: 23778314      PMCID: PMC3906349          DOI: 10.4161/hv.25253

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  30 in total

1.  Healthy carriage of Staphylococcus aureus: its prevalence and importance.

Authors:  R E WILLIAMS
Journal:  Bacteriol Rev       Date:  1963-03

Review 2.  Staphylococcus aureus infections.

Authors:  F D Lowy
Journal:  N Engl J Med       Date:  1998-08-20       Impact factor: 91.245

3.  Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.

Authors:  Vance G Fowler; Keith B Allen; Edson D Moreira; Moustafa Moustafa; Frank Isgro; Helen W Boucher; G Ralph Corey; Yehuda Carmeli; Robert Betts; Jonathan S Hartzel; Ivan S F Chan; Tessie B McNeely; Nicholas A Kartsonis; Dalya Guris; Matthew T Onorato; Steven S Smugar; Mark J DiNubile; Ajoke Sobanjo-ter Meulen
Journal:  JAMA       Date:  2013-04-03       Impact factor: 56.272

4.  Use of coagulase gene (coa) repeat region nucleotide sequences for typing of methicillin-resistant Staphylococcus aureus strains.

Authors:  B Shopsin; M Gomez; M Waddington; M Riehman; B N Kreiswirth
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains.

Authors:  B Shopsin; M Gomez; S O Montgomery; D H Smith; M Waddington; D E Dodge; D A Bost; M Riehman; S Naidich; B N Kreiswirth
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

6.  Passage of heme-iron across the envelope of Staphylococcus aureus.

Authors:  Sarkis K Mazmanian; Eric P Skaar; Andrew H Gaspar; Munir Humayun; Piotr Gornicki; Joanna Jelenska; Andrzej Joachmiak; Dominique M Missiakas; Olaf Schneewind
Journal:  Science       Date:  2003-02-07       Impact factor: 47.728

Review 7.  Iron-regulated surface determinants (Isd) of Staphylococcus aureus: stealing iron from heme.

Authors:  Eric P Skaar; Olaf Schneewind
Journal:  Microbes Infect       Date:  2004-04       Impact factor: 2.700

8.  Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance.

Authors:  J P Steinberg; C C Clark; B O Hackman
Journal:  Clin Infect Dis       Date:  1996-08       Impact factor: 9.079

9.  Predicting the Staphylococcus aureus nasal carrier state: derivation and validation of a "culture rule".

Authors:  Jan L Nouwen; Alewijn Ott; Marjolein F Q Kluytmans-Vandenbergh; Hélène A M Boelens; Albert Hofman; Alex van Belkum; Henri A Verbrugh
Journal:  Clin Infect Dis       Date:  2004-08-26       Impact factor: 9.079

10.  Bacteremia in patients on chronic hemodialysis. A multicenter prospective survey.

Authors:  M Kessler; B Hoen; D Mayeux; D Hestin; C Fontenaille
Journal:  Nephron       Date:  1993       Impact factor: 2.847

View more
  10 in total

1.  Interleukin-10 (IL-10) Produced by Mutant Toxic Shock Syndrome Toxin 1 Vaccine-Induced Memory T Cells Downregulates IL-17 Production and Abrogates the Protective Effect against Staphylococcus aureus Infection.

Authors:  Kouji Narita; Dong-Liang Hu; Krisana Asano; Akio Nakane
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

2.  Safety of Staphylococcus aureus four-antigen and three-antigen vaccines in healthy adults: A meta-analysis of randomized controlled trials.

Authors:  Xiaoqun Xu; Houyong Zhu; Huoyang Lv
Journal:  Hum Vaccin Immunother       Date:  2017-12-06       Impact factor: 3.452

Review 3.  Where does a Staphylococcus aureus vaccine stand?

Authors:  V G Fowler; R A Proctor
Journal:  Clin Microbiol Infect       Date:  2014-05       Impact factor: 8.067

Review 4.  Covering all the Bases: Preclinical Development of an Effective Staphylococcus aureus Vaccine.

Authors:  Ingrid L Scully; Paul A Liberator; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Front Immunol       Date:  2014-03-24       Impact factor: 7.561

Review 5.  Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.

Authors:  Aisling F Brown; John M Leech; Thomas R Rogers; Rachel M McLoughlin
Journal:  Front Immunol       Date:  2014-01-08       Impact factor: 7.561

6.  Evaluation of approaches to monitor Staphylococcus aureus virulence factor expression during human disease.

Authors:  Wouter Rozemeijer; Pamela Fink; Eduardo Rojas; C Hal Jones; Danka Pavliakova; Peter Giardina; Ellen Murphy; Paul Liberator; Qin Jiang; Douglas Girgenti; Remco P H Peters; Paul H M Savelkoul; Kathrin U Jansen; Annaliesa S Anderson; Jan Kluytmans
Journal:  PLoS One       Date:  2015-02-26       Impact factor: 3.240

7.  Adaptive immune response to lipoproteins of Staphylococcus aureus in healthy subjects.

Authors:  Chi Hai Vu; Julia Kolata; Sebastian Stentzel; Anica Beyer; Manuela Gesell Salazar; Leif Steil; Jan Pané-Farré; Vanessa Rühmling; Susanne Engelmann; Friedrich Götz; Jan Maarten van Dijl; Michael Hecker; Ulrike Mäder; Frank Schmidt; Uwe Völker; Barbara M Bröker
Journal:  Proteomics       Date:  2016-08-03       Impact factor: 3.984

8.  Human VH1-69 Gene-Encoded Human Monoclonal Antibodies against Staphylococcus aureus IsdB Use at Least Three Distinct Modes of Binding To Inhibit Bacterial Growth and Pathogenesis.

Authors:  Monique R Bennett; Jinhui Dong; Robin G Bombardi; Cinque Soto; Helen M Parrington; Rachel S Nargi; Clara T Schoeder; Marcus B Nagel; Kevin L Schey; Jens Meiler; Eric P Skaar; James E Crowe
Journal:  mBio       Date:  2019-10-22       Impact factor: 7.867

9.  A model-based analysis: what potential could there be for a S. aureus vaccine in a hospital setting on top of other preventative measures?

Authors:  Cosmina Hogea; Thierry Van Effelterre; Adrian Cassidy
Journal:  BMC Infect Dis       Date:  2014-05-28       Impact factor: 3.090

Review 10.  Neutrophil-Mediated Phagocytosis of Staphylococcus aureus.

Authors:  Kok P M van Kessel; Jovanka Bestebroer; Jos A G van Strijp
Journal:  Front Immunol       Date:  2014-09-26       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.